Link TW, Carnevale JA, Goldberg JL, Jones C, Kocharian G, Boddu SR, Lin N, Patsalides A, Y Gobin P, Knopman J.
2021.
Multiple pipeline embolization devices improves aneurysm occlusion without increasing morbidity: A single center experience of 140 cases.. J Clin Neurosci. 86:129-135.
Link TW, Carnevale JA, Goldberg JL, Jones C, Kocharian G, Boddu SR, Lin N, Patsalides A, Y Gobin P, Knopman J.
2021.
Multiple pipeline embolization devices improves aneurysm occlusion without increasing morbidity: A single center experience of 140 cases.. J Clin Neurosci. 86:129-135.
Schmidt FA, Lekuya HM, Kirnaz S, Hernandez RNick, Hussain I, Chang L, Navarro-Ramirez R, Wipplinger C, Rawanduzy C, Härtl R.
2021.
Novel MIS 3D NAV Single Step Pedicle Screw System (SSPSS): Workflow, Accuracy and Initial Clinical Experience.. Global Spine J. :2192568220976393.
Lee NJ, Joaquim AF, Boddapati V, Mathew J, Park P, Kim JS, Sardar ZM, Lehman RA, K Riew D.
2021.
Revision Anterior Cervical Disc Arthroplasty: A National Analysis of the Associated Indications, Procedures, and Postoperative Outcomes.. Global Spine J. :2192568220979140.
Fehlings MG, Badhiwala JH, Ahn H, H Farhadi F, Shaffrey CI, Nassr A, Mummaneni P, Arnold PM, W Jacobs B, K Riew D et al..
2021.
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.. Lancet Neurol. 20(2):98-106.
Fehlings MG, Badhiwala JH, Ahn H, H Farhadi F, Shaffrey CI, Nassr A, Mummaneni P, Arnold PM, W Jacobs B, K Riew D et al..
2021.
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.. Lancet Neurol. 20(2):98-106.
Fehlings MG, Badhiwala JH, Ahn H, H Farhadi F, Shaffrey CI, Nassr A, Mummaneni P, Arnold PM, W Jacobs B, K Riew D et al..
2021.
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.. Lancet Neurol. 20(2):98-106.